Core Viewpoint - The announcement by Times New Materials indicates a planned equity transfer from its controlling shareholder, CRRC Zhuzhou Electric Locomotive Research Institute, to China CRRC, which will not change the company's control structure or operational activities [1] Group 1: Equity Transfer Details - The equity transfer is part of the State-owned Assets Supervision and Administration Commission's initiative to streamline ownership structures [1] - After the transfer, China CRRC will become the controlling shareholder, but the overall equity percentage held by China CRRC will remain unchanged [1] - The actual controller of the company will still be the State-owned Assets Supervision and Administration Commission, ensuring continuity in control [1] Group 2: Impact on Operations - The equity transfer is not expected to affect the normal production and operations of the company [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01766 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,371,066,040 | RMB | | 1 | RMB | | 4,371,066,040 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 4,371,066,040 | RMB | | | 1 RMB | | 4,371,066,040 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國中車股份有限公司 呈交日期: 2025年9月30日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01766 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,371,066,040 | RMB | | 1 | RMB | | 4,371,066,040 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 4,371,066,040 | RMB | | | 1 RMB | | 4,371,066,040 | II. 已發行 ...

Core Viewpoint - China CRRC Corporation Limited (01766) has seen a stock increase of over 4%, currently at 6.1 HKD, with a trading volume of 73.42 million HKD, following the announcement of several significant contracts totaling approximately 54.34 billion RMB [1][2][3] Group 1: Contract Details - The company’s subsidiary in the high-speed train sector signed sales contracts with China National Railway Group totaling approximately 37.82 billion RMB [1] - The locomotive subsidiary entered into sales and maintenance contracts with China National Railway Group, Daqin Railway Co., Ltd., and Luxembourg Nexrail AssetCo S.à.r.1., amounting to about 9.45 billion RMB [1] - Contracts for urban rail vehicle sales and maintenance were signed with Changchun Metro Co., Shenyang Metro Group, and Buenos Aires Subterraneos, totaling around 3.48 billion RMB [1] - The freight subsidiary signed sales contracts with China National Railway Group worth approximately 2.48 billion RMB [1] - Additionally, the freight subsidiary signed repair contracts with various railway bureaus under China National Railway Group, totaling about 1.11 billion RMB [2] Group 2: Financial Impact - The total value of these contracts represents approximately 22% of the company's projected revenue for 2024 under Chinese accounting standards [3]

Major Events - Lai Kai Pharmaceutical-B (02105) reported positive preliminary results from Phase I clinical MAD study, with LAE102 showing encouraging trends in muscle gain and fat loss [1] - Fuhong Hanlin (02696) received FDA approval for the Phase I clinical trial application of HLX13 for first-line treatment of unresectable hepatocellular carcinoma (HCC) patients [1] - Ningmeng Media (09857) has commenced filming the urban medical emotional drama "Asking Heart 2" [1] - CRRC Corporation (01766) and its subsidiaries signed significant contracts totaling approximately 54.34 billion [1] - Heng Rui Pharmaceutical (01276) received approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] - Hema Medical (03309) entered into a tripartite global licensing and collaboration agreement with Gilead and Hanmi regarding enecuidar [1] - Jinfang Pharmaceutical-B (02595) completed the enrollment of the first patient in the Phase I/II clinical trial of the molecular glue Pan RAS(ON) inhibitor GFH276 for RAS mutant cancer patients [1] - Gao Shi Medical (02407) obtained international certification for its medical device quality management system [1] Operating Performance - Shenzhen Expressway Company (00548) reported toll revenue of 114 million for the Outer Ring project in August [1] - China National Automobile (00026) announced an annual performance with a post-tax loss attributable to shareholders of 185 million HKD, a year-on-year reduction of 29.64% [1] - OKURA HOLDINGS (01655) reported an annual profit attributable to shareholders of 1.342 billion JPY, a year-on-year decrease of 34.34% [1] - Elephant Future Group (02309) disclosed an annual performance with a loss attributable to owners of approximately 314 million HKD, a year-on-year increase of 71.77% [1] - Henghe Group (00513) reported an annual performance with a loss attributable to owners of approximately 259 million HKD, a year-on-year increase of 0.7% [1]

Core Insights - China CRRC celebrated its 10th anniversary since restructuring, emphasizing its commitment to brand development and high-quality growth in the rail transportation equipment industry [2] - The company introduced the "Dingxin" brand value contribution management model and the "Zhuolun" AI model, aiming to enhance brand value management through data-driven approaches [2] - The publication of "A Brief History of CRRC" highlights the company's 144-year journey and its role in the development of China's rail transportation industry [3] Brand Development Strategy - China CRRC has implemented a brand-led strategy, integrating brand value enhancement into all operational processes, which has strengthened its core competitiveness [4] - The "Xingchi Science Popularization" project aims to promote advanced equipment technology and green living concepts, further enhancing brand value [4] - The company has achieved significant milestones, including the development of the "Fuxing" series trains, which cover speed ranges from 160 km/h to 400 km/h, marking a transition from "catching up" to "leading" in the industry [4] Future Goals - By 2035, China CRRC aims to establish itself as a world-class brand characterized by product excellence, innovation leadership, and modern governance, enhancing its reputation in high-end equipment manufacturing [5]

（文章来源：证券日报） 证券日报网讯 9月29日晚间，中国中车发布公告称，公司及下属企业于近期（主要为2025年7月至2025 年9月）签订了若干项重大合同，合计金额约543.4亿元人民币。 ...

深圳高速公路股份(00548.HK)：8月梅观高速、机荷东段、机荷西段、沿江项目及外环项目路费收入分别为人民币1344.6万元、6245.8万元、5167.9万元、 7148.5万元及1.14亿元。 湾区发展(00737.HK)：8月，广深高速公路、广珠西线高速公路及沿江高速公路(深圳段)月总路费收入分别约为2.56亿元、1.05亿元及7148.5万元，同比分别 减少0.5%、减少12%及增长1%。 希玛医疗(03309.HK)：希华医药与Gilead及韩美就encequidar订立三方全球授权及合作协议。 公告称，根据协议，希华医药及韩美会将encequidar在病毒学领域的全球独家权利授予 Gilead。待于协议期内达成若干条件及里程碑后，希华医 药将获支付1000万美元首付款，日后有权获得的潜在价款可达最高约7250万美元，并可按低个位数比率在销售净额中抽取使用权费。 智通财经9月29日讯（编辑 冯轶）智通财经为您带来今日港股重要公告 1）公司要闻 中国中车(01766.HK)：公司及下属企业近三个月合计签订约543.4亿的重大合同，总金额约占公司中国会计准则下2024年营业收入的22%。 中国铁建(0 ...

Core Viewpoint - China CNR Corporation Limited (601766.SH) has announced the signing of several significant contracts totaling approximately 54.34 billion RMB, which represents about 22% of the company's projected revenue for 2024 under Chinese accounting standards [1] Group 1 - The total amount of the contracts signed by the company and its subsidiaries is approximately 54.34 billion RMB [1] - The contracts are expected to be executed mainly between July 2025 and September 2025 [1] - The total contract value accounts for around 22% of the company's anticipated operating revenue for the year 2024 [1]

Core Viewpoint - China CRRC Corporation Limited and its subsidiaries have recently signed several significant contracts totaling approximately 54.34 billion RMB, indicating strong demand and growth potential in the rail transport sector [1][2]. Group 1: Contract Details - The subsidiary responsible for high-speed trains signed sales contracts with China National Railway Group totaling approximately 37.82 billion RMB [1]. - The locomotive subsidiary signed sales and maintenance contracts with various entities, including China National Railway Group and Luxembourg Nexrail, totaling about 9.45 billion RMB [1]. - Contracts for urban rail vehicles and maintenance were signed with companies such as Changchun Metro and Buenos Aires Metro, amounting to approximately 3.48 billion RMB [1]. - The freight car subsidiary signed sales contracts with China National Railway Group totaling around 2.48 billion RMB [1]. - Additionally, the freight car subsidiary signed repair contracts with various regional railway companies totaling approximately 1.11 billion RMB [1]. Group 2: Financial Impact - The total value of these contracts represents about 22% of the company's projected revenue for 2024 under Chinese accounting standards [2].